Sanofi Withdraws Teplizumab from FDA Fast-Track Review Amid Leadership Dispute
Sanofi has requested the FDA remove its type 1 diabetes drug teplizumab from a fast-track review program after a dispute between agency staff and acti...
Xeber.world
Revolution Medicines
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
Erasca’s RAS-Targeting Pill Shows Strong Early Results in Pancreatic and Lung Cancer Trials
Erasca’s RAS-targeting pill, ERAS-0015, reduced tumors in 40% of advanced pancreatic cancer patients and 62% of advanced non-small cell lung cancer pa...
Can Erasca Challenge Revolution Medicines as the Next Big Player in Pancreatic Cancer Treatment?
Erasca, valued at nearly $7 billion, is racing to prove its pan-RAS inhibitor ERAS-0015 could rival Revolution Medicines in pancreatic cancer treatmen...
Key Insights from AACR: Chinese Biotech, Oncology Communication Gaps, and Breakthroughs in RAS Inhibitors
The final edition of STAT's AACR in 30 seconds newsletter highlights critical discussions on Chinese biotech, oncology communication challenges, and g...
Revolution Medicines Unveils Promising KRAS Drug Data and Novel RAS Inhibitor at AACR 2024
Revolution Medicines presented strong clinical trial data for its next-generation KRAS inhibitor, daraxonrasib, in advanced pancreatic cancer at the A...
Revolution Medicines’ KRAS Drug Shows Strong Results at AACR 2024; NCI Director Addresses Funding Concerns
Revolution Medicines’ experimental KRAS drug, daraxonrasib, doubled survival rates in second-line pancreatic cancer patients compared to chemotherapy....